<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title-group><journal-title>Current Oncology</journal-title></journal-title-group><issn pub-type="ppub">1198-0052</issn><issn pub-type="epub">1718-7729</issn><publisher><publisher-name>Multimed Inc.</publisher-name><publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19478898</article-id><article-id pub-id-type="pmc">2687802</article-id><article-id pub-id-type="publisher-id">co16-s1-s45</article-id><article-categories><subj-group subj-group-type="heading"><subject>Urologic Oncology</subject></subj-group></article-categories><title-group><article-title>Targeted therapies for renal cell carcinoma: more gains from using them again</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gan</surname><given-names>H.K.</given-names></name><degrees>MD PhD</degrees><xref ref-type="author-notes" rid="fn1-co16-s1-s45">*</xref></contrib><contrib contrib-type="author"><name><surname>Seruga</surname><given-names>B.</given-names></name><degrees>MD MSc</degrees><xref ref-type="author-notes" rid="fn1-co16-s1-s45">*</xref></contrib><contrib contrib-type="author"><name><surname>Knox</surname><given-names>J.J.</given-names></name><degrees>MD MSc</degrees><xref ref-type="author-notes" rid="fn1-co16-s1-s45">*</xref><xref ref-type="corresp" rid="c1-co16-s1-s45"/></contrib></contrib-group><author-notes><fn id="fn1-co16-s1-s45"><label>*</label><p>Princess Margaret Hospital, Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON.</p></fn><corresp id="c1-co16-s1-s45">Correspondence to: Jennifer J. Knox, Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2 M9. E-mail:
<email>jennifer.knox@uhn.on.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2009</year></pub-date><volume>16</volume><issue>Suppl 1</issue><fpage>S45</fpage><lpage>S51</lpage><permissions><copyright-statement>2009 Multimed Inc.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The development of molecularly targeted agents that inhibit pathways critical to the development of renal cell carcinoma has significantly improved outcomes in patients with these cancers. Compelling scientific and phase <sc>iii</sc> data have made the use of molecularly targeted agents the standard of care in first-line treatment. Now, available data show that re-treating patients with other tyrosine kinase inhibitors after they progress on sunitinib or sorafenib, or both, is beneficial. A large phase <sc>iii</sc> trial recently showed that, as compared with placebo, treatment with everolimus, an inhibitor of the mammalian target of rapamycin (m<sc>tor</sc>), almost halved the risk of progression (37% vs. 65%) and doubled the median progression-free survival (4 months vs. 2 months). Overall survival was not improved in that study, likely reflecting treatment crossover in the placebo arm, but these data position everolimus as the second-line standard of care. A consistent and growing body of literature also suggests that re-treatment with other kinase inhibitors that the patient has not previously encountered is a reasonable option. Outcomes of initial treatment with sunitinib or sorafenib (or both) should not deter the use of second-line targeted therapy, because the first-line use of targeted agents does not appear to be predictive of outcomes with second-line therapy. However, in view of poor absolute outcomes after second-line treatment and the benefits seen with rationally developed targeted agents in the first-line setting, enrolment of second- and subsequent-line patients in further trials would be preferable.</p></abstract><kwd-group><kwd>Renal cell carcinoma</kwd><kwd>second-line therapy</kwd><kwd>sunitinib</kwd><kwd>sorafenib</kwd><kwd>everolimus</kwd><kwd>temsirolimus</kwd><kwd>bevacizumab</kwd></kwd-group></article-meta></front><body><sec><label>1.</label><title>INTRODUCTION</title><p>In 2005, renal cell carcinoma (<sc>rcc</sc>) was the ninth most common cancer in Canada, with an incidence of 1 per 10,000 population <xref ref-type="bibr" rid="b1-co16-s1-s45">1</xref>, and in that year, the disease was responsible for 2% of the total cost of cancer ($17 billion) <xref ref-type="bibr" rid="b2-co16-s1-s45">2</xref>. Until recently, patients with metastatic disease had limited treatment options, and their 5-year survival was approximately 20% <xref ref-type="bibr" rid="b3-co16-s1-s45">3</xref>. Moreover, tumours in <sc>rcc</sc> rarely responded to chemotherapy and radiotherapy <xref ref-type="bibr" rid="b3-co16-s1-s45">3</xref>. Cytokine therapy (interferon alfa or interleukin 2) had modest efficacy, with a response rate of 12% and a median survival of 13 months in a recent meta-analysis <xref ref-type="bibr" rid="b4-co16-s1-s45">4</xref>. However, since the development of molecularly targeted therapies (<xref ref-type="table" rid="t1-co16-s1-s45">Table <sc>i</sc></xref>) that inhibit the pathways important in the pathogenesis of <sc>rcc</sc> (<xref ref-type="fig" rid="f1-co16-s1-s45">Figure 1</xref>), the outlook has improved.</p></sec><sec sec-type="discussion"><label>2.</label><title>DISCUSSION</title><sec><label>2.1</label><title>Epidemiology and Biology of <sc>rcc</sc></title><p>Loss of the von Hippel&#x02013;Lindau (<sc>vhl</sc>) tumour suppressor is a pivotal event in both hereditary and sporadic <sc>rcc</sc> (<xref ref-type="fig" rid="f1-co16-s1-s45">Figure 1</xref>) <xref ref-type="bibr" rid="b3-co16-s1-s45">3</xref>,<xref ref-type="bibr" rid="b11-co16-s1-s45">11</xref>. The resultant overactivity of the hypoxia-inducible factor (<sc>hif</sc>) pathway leads to overexpression of a set of hypoxia-related genes [for example, vascular endothelial growth factor, platelet-derived growth factor B (<sc>pdgfrb</sc>)] and activation of a number of pathways [for example, the phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (m<sc>tor</sc>) and <italic>ras</italic> signal transduction protein (Ras)/protein encoded by the murine leukemia viral oncogene homolog (Raf)/mitogen-activated protein kinase (Mek)/extracellular signal-regulated kinase (Erk) pathways] <xref ref-type="bibr" rid="b12-co16-s1-s45">12</xref>. Signalling through m<sc>tor</sc> is present in most clear-cell <sc>rcc</sc>
<sup>13,14.</sup> In addition to effects on tumour proliferation, angiogenesis, and apoptosis, activation of m<sc>tor</sc> may also potentiate the activity of <sc>hif</sc>
<xref ref-type="bibr" rid="b12-co16-s1-s45">12</xref>. Inhibition of m<sc>tor</sc> results in tumour inhibition <italic>in vitro</italic>
<xref ref-type="bibr" rid="b13-co16-s1-s45">13</xref> and <italic>in vivo</italic>
<xref ref-type="bibr" rid="b15-co16-s1-s45">15</xref>.</p><p>Interestingly, the epithelial growth factor receptor (<sc>egfr</sc>) pathway is also important to renal oncogenesis. Expression of <sc>egfr</sc> occurs at high frequency in <sc>rcc</sc> (70%&#x02013;90%) <xref ref-type="bibr" rid="b16-co16-s1-s45">16</xref>&#x02013;<xref ref-type="bibr" rid="b18-co16-s1-s45">18</xref>, and loss of <sc>vhl</sc> causes increased expression of transforming growth factor &#x003b1; <xref ref-type="bibr" rid="b19-co16-s1-s45">19</xref> through <sc>hif</sc>-2&#x003b1;&#x02013;dependent mechanisms <xref ref-type="bibr" rid="b20-co16-s1-s45">20</xref>&#x02013;<xref ref-type="bibr" rid="b22-co16-s1-s45">22</xref>. Inhibition of this dysregulated autocrine loop is sufficient to reduce or abolish tumour growth in multiple <sc>vhl</sc>&#x02013;/&#x02013; <sc>rcc</sc> cell lines <xref ref-type="bibr" rid="b20-co16-s1-s45">20</xref>,<xref ref-type="bibr" rid="b21-co16-s1-s45">21</xref>.</p></sec><sec><label>2.2</label><title>First-line Treatment with a Targeted Agent</title><p>Treatment with a number of targeted agents (<xref ref-type="table" rid="t1-co16-s1-s45">Table <sc>i</sc></xref>) is now accepted as the standard of care in patients with metastatic <sc>rcc</sc>. In untreated patients, sunitinib <xref ref-type="bibr" rid="b23-co16-s1-s45">23</xref>, temsirolimus <xref ref-type="bibr" rid="b24-co16-s1-s45">24</xref>, and bevacizumab (when combined with interferon alfa) <xref ref-type="bibr" rid="b25-co16-s1-s45">25</xref> were all found to be superior to interferon alfa alone. For example, Motzer <italic>et al.</italic> and Cella <italic>et al.</italic>
<xref ref-type="bibr" rid="b23-co16-s1-s45">23</xref>,<xref ref-type="bibr" rid="b26-co16-s1-s45">26</xref> showed that patients treated with sunitinib experienced improved progression-free survival [<sc>pfs</sc>: 11 months vs. 5 months; hazard ratio (<sc>hr</sc>): 0.42; 95% confidence interval (<sc>ci</sc>): 0.32 to 0.54; <italic>p</italic> &#x0003c; 0.001), an improved objective response rate (<sc>orr</sc>: 31% vs. 6%; <italic>p</italic> &#x0003c; 0.001), and improved quality of life. Similar benefits were also seen in patients who had received prior cytokine therapy <xref ref-type="bibr" rid="b27-co16-s1-s45">27</xref>. In that group, treatment with sorafenib was superior to placebo with regard to <sc>pfs</sc> (6 months vs. 3 months; <sc>hr</sc>: 0.44; 95% <sc>ci</sc>: 0.35 to 0.55; <italic>p</italic> &#x0003c; 0.01) and the disease control rate (84% vs. 55%; <italic>p</italic> &#x0003c; 0.001). Quality of life was also improved in patients receiving sorafenib as compared with those receiving placebo <xref ref-type="bibr" rid="b28-co16-s1-s45">28</xref>. Only the <sc>egfr</sc> inhibitors failed to deliver substantial therapeutic benefit, either as single agents <xref ref-type="bibr" rid="b17-co16-s1-s45">17</xref>,<xref ref-type="bibr" rid="b18-co16-s1-s45">18</xref>,<xref ref-type="bibr" rid="b29-co16-s1-s45">29</xref>&#x02013;<xref ref-type="bibr" rid="b31-co16-s1-s45">31</xref> or in combination with agents such as bevacizumab <xref ref-type="bibr" rid="b32-co16-s1-s45">32</xref>.</p></sec><sec><label>2.3</label><title>Second-line Treatment After Failure with a First-line Targeted Agent</title><p>Until recently, little evidence was available to guide therapy once patients had progressed on first-line treatment with a targeted agent. There is certainly a need to offer treatments to this patient population, not uncommonly encountered in clinical practice and often of appropriate performance status to tolerate more therapy. Re-treatment with another targeted agent has become commonplace practice despite the lack of prospective data <xref ref-type="bibr" rid="b33-co16-s1-s45">33</xref>, and a number of retrospective studies have now been published about this approach (<xref ref-type="table" rid="t2-co16-s1-s45">Table <sc>ii</sc></xref>). In all but two reports, the clinical benefit rate (complete response/partial response/stable disease) exceeded 50%, and in most cases, it reached 70% or better. In most reports, the median duration of benefit was 6 months or more. Re-treatment was generally well tolerated, with the most common grade 3 toxicities being fatigue, hypertension, and hand&#x02013;foot syndrome.</p><p>Prior response to first-line targeted treatment did not predict response to second-line treatment <xref ref-type="bibr" rid="b34-co16-s1-s45">34</xref>&#x02013;<xref ref-type="bibr" rid="b37-co16-s1-s45">37</xref>. As with other targeted therapies <xref ref-type="bibr" rid="b38-co16-s1-s45">38</xref>, this lack of cross-resistance is thought to indicate incomplete suppression of tumour pathways with initial therapy. Further evidence of activity has been provided by the large prospective expanded-access programs of sorafenib 37 and sunitinib 39, which reported on 2488 and 2341 patients respectively. These programs showed that clinical benefit rates in these populations (84% and 52% respectively) were similar to those reported in phase iii trials. A substantial minority of patients previously exposed to targeted therapies also appeared to derive benefit from sunitinib and sorafenib in these programs.</p><p>The best evidence to date is provided by Motzer <italic>et al</italic>. <xref ref-type="bibr" rid="b47-co16-s1-s45">47</xref>, who reported a positive phase <sc>iii</sc> trial in this clinical setting. Patients who had progressed on sunitinib or sorafenib (or both) were randomized to either the m<sc>tor</sc> inhibitor everolimus (10 mg orally, once daily) or to placebo. Although patients from all prognostic groups were enrolled into the trial, approximately half the patients had an intermediate prognosis. The primary endpoint was <sc>pfs</sc> as determined by independent reviewers. The trial was halted early when an interim analysis indicated a substantial and significant difference in <sc>pfs</sc> in favour of the everolimus group. The progression rate was 37% in the everolimus group as compared with 65% in the placebo group (<sc>hr</sc>: 0.30; 95% <sc>ci</sc>: 0.22 to 0.40; <italic>p</italic> &#x0003c; 0.0001). Median <sc>pfs</sc> was 4.0 months (95% <sc>ci</sc>: 3.7 to 5.5 months) in the everolimus group as compared with 1.9 months (95% <sc>ci</sc>: 1.8 to 1.9 months) in the control group. Median overall survival (<sc>os</sc>) had not been reached in the everolimus arm (in excess of 10 months as compared with 8.8 months in the placebo group). The difference in <sc>os</sc> did not reach statistical significance, likely as a result of the planned crossover from placebo to everolimus on study. Although more stomatitis (40% vs. 8%), rash (25% vs. 4%), and fatigue (20% vs. 16%) occurred in the everolimus group, these side effects were mostly mild or moderate in severity. Pneumonitis (any grade) was detected in 22 patients in the everolimus group (8%), but only 8 patients <xref ref-type="bibr" rid="b3-co16-s1-s45">3</xref> had grade 3 pneumonitis. Quality of life was equivalent in both study arms.</p><p>At this time, everolimus can reasonably be considered to be the preferred second-line treatment after initial failure of sunitinib or sorafenib. Although <sc>os</sc> is always preferable as the primary endpoint in phase <sc>iii</sc> trials, the use of <sc>pfs</sc> in the Motzer study is an acceptable surrogate, and the overall case supporting the efficacy of everolimus as a second-line treatment is strong <xref ref-type="bibr" rid="b48-co16-s1-s45">48</xref>. Although everolimus is not yet approved in Canada for metastatic <sc>rcc</sc>, temsirolimus could be considered in this setting, given that it is currently approved in Canada and has a similar mechanism of activity. Once completed, two phase <sc>iii</sc> trials currently in progress may affect this choice. The first randomizes patients to temsirolimus or sorafenib as second-line therapy after progression on sunitinib (search for &#x0201c;NCT00474786&#x0201d; at <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov/ct2/search">www.clinicaltrials.gov/ct2/search</ext-link>). The second randomizes patients who failed a previous systemic treatment, which may be a tyrosine kinase inhibitor, to either sorafenib or axitinib (search for &#x0201c;NCT00678392&#x0201d; at <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov/ct2/search">www.clinicaltrials.gov/ct2/search</ext-link>).</p></sec></sec><sec sec-type="conclusions"><label>3.</label><title>CONCLUSIONS</title><p>Inhibitors of multiple kinases such as sunitinib and sorafenib are now established as standard first-line therapy in patients with <sc>rcc</sc>. When disease progression occurs after such therapy, there is clearly more benefit to be gained by re-treating these patients with another targeted agent. Everolimus is the drug of choice at the present time, and we expect it to obtain approval for this indication in Canada soon. Until such time as approval is forthcoming, temsirolimus (if available) could be substituted, given its similar mechanism of action. It would also not be unreasonable to use any of the targeted agents in <xref ref-type="table" rid="t2-co16-s1-s45">Table <sc>ii</sc></xref> (if available) to treat patients with progressive <sc>rcc</sc> who have not previously been exposed to those agents. However, the benefits seen with rationally-developed targeted agents in the first-line setting strongly suggest that it is more appropriate to enrol those patients into clinical trials. Research priorities include the evaluation of predictive biomarkers to allow for patient enrichment, optimization of drug sequencing [concurrent vs. sequential, and simultaneous blockade at several points of the same pathway (vertical blockade) vs. blockade of several collateral pathways (horizontal blockade)], and identification of other effective drugs&#x02014;for example, histone deacetylase <xref ref-type="bibr" rid="b49-co16-s1-s45">49</xref>,<xref ref-type="bibr" rid="b50-co16-s1-s45">50</xref>.</p></sec></body><back><ref-list><title>4. REFERENCES</title><ref id="b1-co16-s1-s45"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Statistics Canada, Health Statistics Division</collab></person-group><source>Cancer Incidence in Canada: 2004 to 2005</source><publisher-loc>Ottawa</publisher-loc><publisher-name>Minister of Industry</publisher-name><year>2007</year><comment>[Available online at: dsp-psd.pwgsc.gc.ca/collection_2007/statcan/82-231-X/82-231-XIE2007001.pdf; cited January 19, 2009]</comment></element-citation></ref><ref id="b2-co16-s1-s45"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abugaber</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>K</given-names></name><name><surname>Danchenko</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cost of illness of renal cell carcinoma in Canada [abstract 15560]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=32312">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=32312</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b3-co16-s1-s45"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>HT</given-names></name><name><surname>McGovern</surname><given-names>FJ</given-names></name></person-group><article-title>Renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>2477</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16339096</pub-id></element-citation></ref><ref id="b4-co16-s1-s45"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppin</surname><given-names>C</given-names></name></person-group><article-title>Immunotherapy for renal cell cancer in the era of targeted therapy</article-title><source>Exp Rev Anticancer Ther</source><year>2008</year><volume>8</volume><fpage>907</fpage><lpage>19</lpage></element-citation></ref><ref id="b5-co16-s1-s45"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendel</surname><given-names>DB</given-names></name><name><surname>Laird</surname><given-names>AD</given-names></name><name><surname>Xin</surname><given-names>X</given-names></name><etal/></person-group><article-title><italic>In vivo</italic> antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>327</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">12538485</pub-id></element-citation></ref><ref id="b6-co16-s1-s45"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>SM</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><etal/></person-group><article-title>BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/Mek/Erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>7099</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">15466206</pub-id></element-citation></ref><ref id="b7-co16-s1-s45"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlomagno</surname><given-names>F</given-names></name><name><surname>Anaganti</surname><given-names>S</given-names></name><name><surname>Guida</surname><given-names>T</given-names></name><etal/></person-group><article-title>BAY 43-9006 inhibition of oncogenic RET mutants</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>326</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16507829</pub-id></element-citation></ref><ref id="b8-co16-s1-s45"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Tourneau</surname><given-names>C</given-names></name><name><surname>Faivre</surname><given-names>S</given-names></name><name><surname>Serova</surname><given-names>M</given-names></name><name><surname>Raymond</surname><given-names>E</given-names></name></person-group><article-title>m<sc>tor</sc> C1 inhibitors: is temsirolimus in renal cancer telling us how they really work?</article-title><source>Br J Cancer</source><year>2008</year><volume>99</volume><fpage>1197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">18797463</pub-id></element-citation></ref><ref id="b9-co16-s1-s45"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonpavde</surname><given-names>G</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name></person-group><article-title>Axitinib for renal cell carcinoma</article-title><source>Expert Opin Investig Drugs</source><year>2008</year><volume>17</volume><fpage>741</fpage><lpage>8</lpage></element-citation></ref><ref id="b10-co16-s1-s45"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presta</surname><given-names>LG</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>4593</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9377574</pub-id></element-citation></ref><ref id="b11-co16-s1-s45"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelin</surname><given-names>WG</given-names><suffix>Jr</suffix></name></person-group><article-title>The von Hippel&#x02013;Lindau tumor suppressor protein and clear cell renal carcinoma</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>680s</fpage><lpage>4s</lpage><pub-id pub-id-type="pmid">17255293</pub-id></element-citation></ref><ref id="b12-co16-s1-s45"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>D</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Regan</surname><given-names>M</given-names></name><name><surname>Mier</surname><given-names>JW</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name></person-group><article-title>The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>758s</fpage><lpage>63s</lpage><pub-id pub-id-type="pmid">17255306</pub-id></element-citation></ref><ref id="b13-co16-s1-s45"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robb</surname><given-names>VA</given-names></name><name><surname>Karbowniczek</surname><given-names>M</given-names></name><name><surname>Klein&#x02013;Szanto</surname><given-names>AJ</given-names></name><name><surname>Henske</surname><given-names>EP</given-names></name></person-group><article-title>Activation of the m<sc>tor</sc> signaling pathway in renal clear cell carcinoma</article-title><source>J Urol</source><year>2007</year><volume>177</volume><fpage>346</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17162089</pub-id></element-citation></ref><ref id="b14-co16-s1-s45"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>PL</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Prichard</surname><given-names>JW</given-names></name><name><surname>Lun</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>RE</given-names></name></person-group><article-title>Morphoproteomic and molecular concomitants of an overexpressed and activated m<sc>tor</sc> pathway in renal cell carcinomas</article-title><source>Ann Clin Lab Sci</source><year>2006</year><volume>36</volume><fpage>283</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16951269</pub-id></element-citation></ref><ref id="b15-co16-s1-s45"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sourbier</surname><given-names>C</given-names></name><name><surname>Lindner</surname><given-names>V</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><etal/></person-group><article-title>The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>5130</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16707436</pub-id></element-citation></ref><ref id="b16-co16-s1-s45"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asakuma</surname><given-names>J</given-names></name><name><surname>Sumitomo</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name></person-group><article-title>Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma</article-title><source>J Urol</source><year>2004</year><volume>171</volume><fpage>897</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">14713849</pub-id></element-citation></ref><ref id="b17-co16-s1-s45"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Hawkins</surname><given-names>R</given-names></name><name><surname>Gardner</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase <sc>iii</sc> clinical trial</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2285</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">18467719</pub-id></element-citation></ref><ref id="b18-co16-s1-s45"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowinsky</surname><given-names>EK</given-names></name><name><surname>Schwartz</surname><given-names>GH</given-names></name><name><surname>Gollob</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3003</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15210739</pub-id></element-citation></ref><ref id="b19-co16-s1-s45"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knebelmann</surname><given-names>B</given-names></name><name><surname>Ananth</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>HT</given-names></name><name><surname>Sukhatme</surname><given-names>VP</given-names></name></person-group><article-title>Transforming growth factor alpha is a target for the von Hippel&#x02013;Lindau tumor suppressor</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>226</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">9443397</pub-id></element-citation></ref><ref id="b20-co16-s1-s45"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunaratnam</surname><given-names>L</given-names></name><name><surname>Morley</surname><given-names>M</given-names></name><name><surname>Franovic</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in <sc>vhl</sc>(&#x02013;/&#x02013;) renal cell carcinoma cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>44966</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12944410</pub-id></element-citation></ref><ref id="b21-co16-s1-s45"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Gunaratnam</surname><given-names>L</given-names></name><name><surname>Morley</surname><given-names>M</given-names></name><name><surname>Franovic</surname><given-names>A</given-names></name><name><surname>Mekhail</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2&#x02013;driven <sc>vhl</sc>&#x02013;/&#x02013; renal cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>5221</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15958567</pub-id></element-citation></ref><ref id="b22-co16-s1-s45"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Paulsen</surname><given-names>N</given-names></name><name><surname>Brychzy</surname><given-names>A</given-names></name><name><surname>Fournier</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Role of transforming growth factor-alpha in von Hippel&#x02013;Lindau (<sc>vhl</sc>)(&#x02013;/&#x02013;) clear cell renal carcinoma cell proliferation: a possible mechanism coupling <sc>vhl</sc> tumor suppressor inactivation and tumorigenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>1387</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11171960</pub-id></element-citation></ref><ref id="b23-co16-s1-s45"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>115</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17215529</pub-id></element-citation></ref><ref id="b24-co16-s1-s45"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudes</surname><given-names>G</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><etal/><collab>on behalf of the Global <sc>arcc</sc> Trial</collab></person-group><article-title>Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>2271</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">17538086</pub-id></element-citation></ref><ref id="b25-co16-s1-s45"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Koralewski</surname><given-names>P</given-names></name><etal/><collab>on behalf of the Avoren Trial investigators</collab></person-group><article-title>Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase <sc>iii</sc> trial</article-title><source>Lancet</source><year>2008</year><volume>370</volume><fpage>2103</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18156031</pub-id></element-citation></ref><ref id="b26-co16-s1-s45"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Cappelleri</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase <sc>iii</sc> randomized trial</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3763</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18669464</pub-id></element-citation></ref><ref id="b27-co16-s1-s45"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>125</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">17215530</pub-id></element-citation></ref><ref id="b28-co16-s1-s45"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>R</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Gondek</surname><given-names>K</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><collab>on behalf of the Sorafenib <sc>targets Clinical Trial Group</sc></collab></person-group><article-title>Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer</article-title><source>Am J Clin Oncol</source><year>2007</year><volume>30</volume><fpage>220</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17551296</pub-id></element-citation></ref><ref id="b29-co16-s1-s45"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name><name><surname>Todd</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase <sc>ii</sc> trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma</article-title><source>Invest New Drugs</source><year>2003</year><volume>21</volume><fpage>99</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">12795534</pub-id></element-citation></ref><ref id="b30-co16-s1-s45"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>B</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Ginsberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase <sc>ii</sc> trial of ZD1839 (Iressa) in patients with advanced renal cell carcinoma</article-title><source>Invest New Drugs</source><year>2003</year><volume>21</volume><fpage>341</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14578682</pub-id></element-citation></ref><ref id="b31-co16-s1-s45"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeram</surname><given-names>M</given-names></name><name><surname>Rowinsky</surname><given-names>EK</given-names></name><name><surname>Weiss</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: a phase <sc>ii</sc>, pharmacokinetic (<sc>pk</sc>) and biological correlative study with <sc>fdg</sc>-<sc>pet</sc> imaging [abstract 3050]</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>22</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=26&#x00026;abstractID=3632">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=26&#x00026;abstractID=3632</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b32-co16-s1-s45"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Kabbinavar</surname><given-names>FF</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4536</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17876014</pub-id></element-citation></ref><ref id="b33-co16-s1-s45"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Rathmell</surname><given-names>WK</given-names></name><name><surname>Godley</surname><given-names>P</given-names></name></person-group><article-title>Renal cell carcinoma</article-title><source>Curr Opin Oncol</source><year>2008</year><volume>20</volume><fpage>300</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18391630</pub-id></element-citation></ref><ref id="b34-co16-s1-s45"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamaskar</surname><given-names>I</given-names></name><name><surname>Garcia</surname><given-names>JA</given-names></name><name><surname>Elson</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy</article-title><source>J Urol</source><year>2008</year><volume>179</volume><fpage>81</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17997441</pub-id></element-citation></ref><ref id="b35-co16-s1-s45"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3743</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18669461</pub-id></element-citation></ref><ref id="b36-co16-s1-s45"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Elson</surname><given-names>P</given-names></name><etal/></person-group><article-title>A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mcc<sc>rcc</sc>) refractory to prior sunitinib or bevacizumab [abstract 346]</article-title><source>Am Soc Clin Oncol Genitourin Cancers Symp</source><year>2008</year><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=54&#x00026;abstractID=20239">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=54&#x00026;abstractID=20239</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b37-co16-s1-s45"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knox</surname><given-names>JJ</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><etal/><collab>on behalf of the <sc>arccs</sc> Investigators</collab></person-group><article-title>The Advanced Renal Cell Carcinoma Sorafenib (<sc>arccs</sc>) expanded access trial in North America: safety and efficacy [abstract 5011]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=34297">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=34297</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b38-co16-s1-s45"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matar</surname><given-names>P</given-names></name><name><surname>Rojo</surname><given-names>F</given-names></name><name><surname>Cassia</surname><given-names>R</given-names></name><etal/></person-group><article-title>Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>6487</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">15475436</pub-id></element-citation></ref><ref id="b39-co16-s1-s45"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname><given-names>ME</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sunitinib in metastatic renal cell carcinoma (<sc>mrcc</sc>): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis [abstract 5010]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=32318">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=32318</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b40-co16-s1-s45"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sablin</surname><given-names>MP</given-names></name><name><surname>Bouaita</surname><given-names>L</given-names></name><name><surname>Balleyguier</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract 5038]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=32197">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=32197</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b41-co16-s1-s45"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepulveda</surname><given-names>J</given-names></name><name><surname>Maroto</surname><given-names>P</given-names></name><name><surname>Andres</surname><given-names>R</given-names></name><etal/></person-group><article-title>Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (m<sc>rcc</sc>): analysis for safety and activity on sunitinib progressive pts [abstract 16100]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=36069">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=36069</ext-link>; cited February 17, 2009]</comment></element-citation></ref><ref id="b42-co16-s1-s45"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudek</surname><given-names>AZ</given-names></name><name><surname>Zolnierek</surname><given-names>J</given-names></name><name><surname>Dham</surname><given-names>A</given-names></name><name><surname>Lindgren</surname><given-names>BR</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name></person-group><article-title>Sequential therapy with sorafenib and sunitinib in renal cell carcinoma</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>61</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19051290</pub-id></element-citation></ref><ref id="b43-co16-s1-s45"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichelberg</surname><given-names>C</given-names></name><name><surname>Heuer</surname><given-names>R</given-names></name><name><surname>Chun</surname><given-names>FK</given-names></name><etal/></person-group><article-title>Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis</article-title><source>Eur Urol</source><year>2008</year><volume>54</volume><fpage>1373</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18692304</pub-id></element-citation></ref><ref id="b44-co16-s1-s45"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Wilding</surname><given-names>GT</given-names></name><name><surname>Hudes</surname><given-names>G</given-names></name><etal/></person-group><article-title>Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (<sc>rcc</sc>) refractory to sorafenib [abstract 5032]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=33225">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=33225</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b45-co16-s1-s45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutcher</surname><given-names>JP</given-names></name><name><surname>Wilding</surname><given-names>G</given-names></name><name><surname>Hudes</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (<sc>rcc</sc>) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone [abstract 5127]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=35034">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=35034</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b46-co16-s1-s45"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whorf</surname><given-names>RC</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name><name><surname>Spigel</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Phase <sc>ii</sc> study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (<sc>rcc</sc>) [abstract 5010]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=34991">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=34991</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b47-co16-s1-s45"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><etal/><collab>on behalf of the <sc>record</sc>-1 Study Group</collab></person-group><article-title>Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase <sc>iii</sc> trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>449</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">18653228</pub-id></element-citation></ref><ref id="b48-co16-s1-s45"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knox</surname><given-names>JJ</given-names></name></person-group><article-title>Progression-free survival as endpoint in metastatic <sc>rcc</sc>?</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>427</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18653227</pub-id></element-citation></ref><ref id="b49-co16-s1-s45"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drabkin</surname><given-names>HA</given-names></name></person-group><article-title>The combination of sorafenib and vorinostat causes synergistic growth inhibition in kidney cancer cells [abstract 402]</article-title><source>Am Soc Clin Oncol Genitourin Cancers Symp</source><year>2008</year><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=54&#x00026;abstractID=20022">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=54&#x00026;abstractID=20022</ext-link>; cited January 19, 2009]</comment></element-citation></ref><ref id="b50-co16-s1-s45"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammers</surname><given-names>HJ</given-names></name><name><surname>Verheul</surname><given-names>H</given-names></name><name><surname>Wilky</surname><given-names>B</given-names></name><etal/></person-group><article-title>Phase <sc>i</sc> safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer [abstract 16094]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=33518">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=33518</ext-link>; cited January 19, 2009]</comment></element-citation></ref></ref-list></back><floats-group><fig id="f1-co16-s1-s45" position="float"><label>FIGURE 1</label><caption><p>Simplified schema of signalling pathways that contribute to renal oncogenesis. <sc>vhl</sc> = Von Hippel&#x02013;Lindau tumour-suppressor protein; <sc>egfr</sc> = epidermal growth factor receptor; <sc>hdac</sc>= histone deacetylase; Hsp90 = heat shock protein 90; <sc>hif</sc> = hypoxia-inducible factor; <sc>tgf</sc>&#x003b1; = transforming growth factor &#x003b1;; <sc>rtk</sc>s = receptor tyrosine kinases; <sc>igfr</sc>-1 = insulin-like growth factor receptor 1; <sc>vegf</sc> = vascular endothelial growth factor; Raf = protein encoded by the murine leukemia viral oncogene homolog; Ras = ras signal transduction protein; <sc>pi</sc>3K = phosphoinositide-3-kinase; <sc>mek</sc> = mitogen-activated protein kinase; <sc>pten</sc> = protein encoded by the phosphatase and tensin homolog gene; <sc>erk</sc> = extracellular signal-regulated kinase; Akt = protein kinase B; m<sc>tor</sc> = mammalian target of rapamycin.</p></caption><graphic xlink:href="co16-s1-s45f1"/></fig><table-wrap id="t1-co16-s1-s45" position="float"><label>TABLE I</label><caption><p>Selected targeted agents in the treatment of renal cell carcinoma (<sc>rcc</sc>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"><italic>Name</italic></th><th valign="middle" align="center" rowspan="1" colspan="1"><italic>Targets</italic></th><th valign="middle" align="left" rowspan="1" colspan="1"><italic>Canadian regulatory status in <sc>rcc</sc></italic></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1">Tyrosine kinase inhibitors</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Sunitinib<xref ref-type="bibr" rid="b5-co16-s1-s45">5</xref>
<break/>&#x02003;&#x02003;&#x02003;(Sutent<xref ref-type="table-fn" rid="tfn1-co16-s1-s45">a</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><sc>vegfr</sc> 1, 2, 3; <sc>pdgfra</sc>, <sc>b</sc>; Flt3; c-Kit; <sc>ret</sc></td><td valign="top" align="left" rowspan="1" colspan="1">Approved for patients with metastatic <sc>rcc</sc> of clear-cell histology and good or intermediate prognosis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Sorafenib <xref ref-type="bibr" rid="b6-co16-s1-s45">6</xref>,<xref ref-type="bibr" rid="b7-co16-s1-s45">7</xref>
<break/>&#x02003;&#x02003;&#x02003;(Nexacar<xref ref-type="table-fn" rid="tfn2-co16-s1-s45">b</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Raf; <sc>vegfr</sc>2, 3; <sc>pdgfrb</sc>; Flt3; c-Kit; <sc>ret</sc></td><td valign="top" align="left" rowspan="1" colspan="1">Approved for patients with locally advanced or metastatic <sc>rcc</sc> who have failed, or are intolerant to, cytokine therapy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Temsirolimus <xref ref-type="bibr" rid="b8-co16-s1-s45">8</xref>
<break/>&#x02003;&#x02003;&#x02003;(Torisel<xref ref-type="table-fn" rid="tfn3-co16-s1-s45">c</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">m<sc>tor</sc></td><td valign="top" align="left" rowspan="1" colspan="1">Approved for patients with metastatic <sc>rcc</sc> (not funded in all provinces)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Axitinib<xref ref-type="bibr" rid="b9-co16-s1-s45">9</xref>
<break/>&#x02003;&#x02003;&#x02003;(Pfizer<xref ref-type="table-fn" rid="tfn1-co16-s1-s45">a</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><sc>vegfr</sc>1, 2, 3; <sc>pdgfra</sc>, <sc>b</sc>; c-Kit</td><td valign="top" align="left" rowspan="1" colspan="1">Not approved</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Everolimus <xref ref-type="bibr" rid="b8-co16-s1-s45">8</xref>
<break/>&#x02003;&#x02003;&#x02003;(Certican<xref ref-type="table-fn" rid="tfn4-co16-s1-s45">d</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">m<sc>tor</sc></td><td valign="top" align="left" rowspan="1" colspan="1">Under consideration</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Monoclonal antibodies</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Bevacizumab <xref ref-type="bibr" rid="b10-co16-s1-s45">10</xref>
<break/>&#x02003;&#x02003;&#x02003;(Avastin<xref ref-type="table-fn" rid="tfn5-co16-s1-s45">e</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><sc>vegf</sc></td><td valign="top" align="left" rowspan="1" colspan="1">Not approved</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-co16-s1-s45"><label><sup>a</sup></label><p> Pfizer Canada, Kirkland, QC.</p></fn><fn id="tfn2-co16-s1-s45"><label><sup>b</sup></label><p>Bayer HealthCare AG, Leverkusen, Germany.</p></fn><fn id="tfn3-co16-s1-s45"><label><sup>c</sup></label><p>Wyeth, Madison, NJ, U.S.A.</p></fn><fn id="tfn4-co16-s1-s45"><label><sup>d</sup></label><p>Novartis Pharmaceuticals, St. Louis, MO, U.S.A.</p></fn><fn id="tfn5-co16-s1-s45"><label><sup>e</sup></label><p>Genentech, San Francisco, CA, U.S.A., and Hoffmann&#x02013;La Roche Ltd., Mississauga, ON.</p></fn><fn id="tfn6-co16-s1-s45"><p><sc>vegfr</sc> = vascular endothelial growth factor receptor; <sc>pdgfra</sc>, <sc>b</sc> = platelet-derived growth factor receptor &#x003b1; and B; Flt3 = fms-related tyrosine kinase 3; Raf = protein encoded by the murine leukemia viral oncogene homolog; m<sc>tor</sc> = mammalian target of rapamycin; <sc>vegf</sc> = vascular endothelial growth factor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-co16-s1-s45" position="float"><label>TABLE II</label><caption><p>Retrospective data regarding the efficacy of second-line targeted therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="2" colspan="1"><italic>Reference</italic></th><th valign="top" align="center" rowspan="2" colspan="1"><italic>Pts (</italic>n<italic>)</italic></th><th valign="top" align="center" colspan="2" rowspan="1"><italic>Targeted treatment</italic></th><th valign="top" align="center" colspan="2" rowspan="1"><italic>Clinical benefit</italic></th><th valign="top" align="center" rowspan="2" colspan="1"><italic>Benefit duration (months)</italic></th><th valign="top" align="center" rowspan="2" colspan="1"><italic>Frequency of grades 3 and 4 toxicities</italic></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1"><italic>First-line</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>Second-line+</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>(%)</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>(CR/PR/SD) (</italic>n<italic>)</italic></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="8" rowspan="1">First-line sunitinib</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Sablin <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b40-co16-s1-s45">40</xref></td><td valign="top" align="left" rowspan="1" colspan="1">22</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">0/15/55</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pfs</sc>: 6</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Sepulveda, <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b41-co16-s1-s45">41</xref></td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib
<break/>plus cytokines (100%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">0/10/60</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>ttp</sc>: 7
<break/><sc>os</sc>: 9</td><td valign="top" align="center" rowspan="1" colspan="1">Fatigue (17%)
<break/>Mucositis (9%)
<break/>Hypertension (9%)
<break/><sc>hfs</sc> (9%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Dudek <italic>et al.</italic>, 2009 <xref ref-type="bibr" rid="b42-co16-s1-s45">42</xref></td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib
<break/>plus cytokines (80%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"><sc>ttp</sc>: 2</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1">First-line sorafenib</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Sablin <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b40-co16-s1-s45">40</xref></td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">0/15/58</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pfs</sc>: 7</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Eichelberg <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b43-co16-s1-s45">43</xref></td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib
<break/>plus cytokines (67%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib</td><td valign="top" align="center" rowspan="1" colspan="1">55</td><td valign="top" align="center" rowspan="1" colspan="1">0/11/44</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pfs</sc>: 10</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>hfs</sc> (3%)
<break/> Leucopenia (3%)
<break/> Platelets (3%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Dudek <italic>et al.</italic>, 2009 <xref ref-type="bibr" rid="b42-co16-s1-s45">42</xref></td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib
<break/>plus cytokines (55%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib</td><td valign="top" align="center" rowspan="1" colspan="1">59</td><td valign="top" align="center" rowspan="1" colspan="1">0/21/38</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>ttp</sc>: 5</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1">First-line sorafenib + sunitinib</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Rini <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b44-co16-s1-s45">44</xref></td><td valign="top" align="left" rowspan="1" colspan="1">62</td><td valign="top" align="left" rowspan="1" colspan="1">Sorafenib (100%)
<break/> plus sunitinib (23%)
<break/> plus cytokines (60%)</td><td valign="top" align="center" rowspan="1" colspan="1">Axitinib</td><td valign="top" align="center" rowspan="1" colspan="1">55</td><td valign="top" align="center" rowspan="1" colspan="1">0/21/34</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Fatigue (18%)
<break/> Hypertension (16%)
<break/><sc>hfs</sc> (11%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Dutcher <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b45-co16-s1-s45">45</xref></td><td valign="top" align="left" rowspan="1" colspan="1">59</td><td valign="top" align="left" rowspan="1" colspan="1">Sorafenib
<break/>plus sunitinib (24%)
<break/>plus cytokines (64%)</td><td valign="top" align="center" rowspan="1" colspan="1">Axitinib</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0/32/68</td><td valign="top" align="left" rowspan="1" colspan="1"><sc>pfs</sc>: approx. 8</td><td valign="top" align="left" rowspan="1" colspan="1">Fatigue (13%)
<break/>Hypertension (11%)
<break/><sc>hfs</sc> (11%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Whorf <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b46-co16-s1-s45">46</xref></td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">Sorafenib (<italic>n</italic>=12), sunitinib (<italic>n</italic>=15), both (<italic>n</italic>=2)</td><td valign="top" align="center" rowspan="1" colspan="1">Bevacizumab and everolimus</td><td valign="top" align="center" rowspan="1" colspan="1">84</td><td valign="top" align="center" rowspan="1" colspan="1">0/19/65</td><td valign="top" align="left" rowspan="1" colspan="1"><sc>pfs</sc>: 11</td><td valign="top" align="left" rowspan="1" colspan="1">Proteinuria (17%)
<break/>Fatigue (7%)
<break/>Stomatitis (7%)</td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1">First-line bevacizumab</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Knox <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b37-co16-s1-s45">37</xref></td><td valign="top" align="left" rowspan="1" colspan="1">197</td><td valign="top" align="left" rowspan="1" colspan="1">Bevacizumab
<break/>plus others (100%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib</td><td valign="top" align="center" rowspan="1" colspan="1">81</td><td valign="top" align="center" rowspan="1" colspan="1">0/3/78</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Rini <italic>et al.</italic>, 2008<xref ref-type="bibr" rid="b35-co16-s1-s45">35</xref></td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">Bevacizumab
<break/>plus others (66%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib</td><td valign="top" align="center" rowspan="1" colspan="1">82</td><td valign="top" align="center" rowspan="1" colspan="1">0/23/59</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pfs</sc>: 8
<break/>
<sc>os</sc>: 12</td><td valign="top" align="center" rowspan="1" colspan="1">Fatigue (34%)
<break/>Hypertension (18%)
<break/><sc>hfs</sc> (10%)</td></tr><tr><td valign="top" align="left" colspan="8" rowspan="1">Other first-line</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Rini <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b36-co16-s1-s45">36</xref></td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1">Bevacizumab (<italic>n</italic>=15) or sunitinib (<italic>n</italic>=22) plus other
<break/> anti-angiogenics (13%) plus cytokines or others (72%)</td><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib</td><td valign="top" align="center" rowspan="1" colspan="1">43</td><td valign="top" align="center" rowspan="1" colspan="1">0/3/40</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>pfs</sc>: 4</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>hfs</sc> (31%)
<break/>Fatigue (17%)
<break/>Hypertension (14%)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">&#x02003;&#x02003;Tamaskar <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b34-co16-s1-s45">34</xref></td><td valign="top" align="left" rowspan="2" colspan="1">30</td><td valign="top" align="left" rowspan="2" colspan="1">Miscellaneous (thalidomide, lenalidomide, bevacizumab, volociximab, AG13736, sorafenib, or sunitinib)</td><td valign="top" align="center" rowspan="1" colspan="1">Sunitinib (<italic>n</italic>=16)</td><td valign="top" align="center" rowspan="1" colspan="1">81</td><td valign="top" align="center" rowspan="1" colspan="1">0/56/25</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>ttp</sc>: 10</td><td valign="top" align="center" rowspan="1" colspan="1"><sc>na</sc></td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">Sorafenib (<italic>n</italic>=14)</td><td valign="top" align="center" rowspan="1" colspan="1">71</td><td valign="top" align="center" rowspan="1" colspan="1">0/7/64</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn7-co16-s1-s45"><p>Pts = patients; <sc>cr</sc> = complete response; <sc>pr</sc> = partial response; <sc>sd</sc> = stable disease; <sc>pfs</sc> = progression-free survival; <sc>na</sc> = not available; <sc>ttp</sc> = time to progression; <sc>os</sc> = overall survival; <sc>hfs</sc> = hand&#x02013;foot syndrome.</p></fn></table-wrap-foot></table-wrap></floats-group></article>